Mäkinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto Korander R, et al. Exome Sequencing of Uterine Leiomyosarcomas Identifies Frequent Mutations in TP53, ATRX, and MED12. PLoS Genet. 2016;12:e1005850 pubmed publisher

Graham M, Kim J, Da J, Brosnan Cashman J, Rizzo A, Baena Del Valle J, et al. Functional Loss of ATRX and TERC Activates Alternative Lengthening of Telomeres (ALT) in LAPC4 Prostate Cancer Cells. Mol Cancer Res. 2019;17:2480-2491 pubmed publisher

Jin C, Hacking S, Komforti M, Nasim M. A Comparison of Death Domain-Associated Protein 6 in Different Endometrial Carcinomas Histotypes. Biomark Insights. 2019;14:1177271919864892 pubmed publisher

Bell W, Meeker A, Rizzo A, Rajpara S, Rosenthal I, Flores Bellver M, et al. A unique telomere DNA expansion phenotype in human retinal rod photoreceptors associated with aging and disease. Brain Pathol. 2019;29:45-52 pubmed publisher

Liverani C, Bongiovanni A, Mercatali L, Foca F, Pieri F, De Vita A, et al. Grading of Neuroendocrine Carcinomas: Correlation of 68Ga-PET/CT Scan with Tissue Biomarkers. Dis Markers. 2018;2018:6878409 pubmed publisher

Hossain M, Ohsaki E, Honda T, Ueda K. Importance of Promyelocytic Leukema Protein (PML) for Kaposi's Sarcoma-Associated Herpesvirus Lytic Replication. Front Microbiol. 2018;9:2324 pubmed publisher

Chou A, Itchins M, de Reuver P, Arena J, Clarkson A, Sheen A, et al. ATRX loss is an independent predictor of poor survival in pancreatic neuroendocrine tumors. Hum Pathol. 2018;82:249-257 pubmed publisher

Ueda H, Akiyama Y, Shimada S, Mogushi K, Serizawa M, Matsumura S, et al. Tumor suppressor functions of DAXX through histone H3.3/H3K9me3 pathway in pancreatic NETs. Endocr Relat Cancer. 2018;25:619-631 pubmed publisher

Panse G, Chrisinger J, Leung C, Ingram D, Khan S, Wani K, et al. Clinicopathological analysis of ATRX, DAXX and NOTCH receptor expression in angiosarcomas. Histopathology. 2018;72:239-247 pubmed publisher

Dagg R, Pickett H, Neumann A, Napier C, Henson J, Teber E, et al. Extensive Proliferation of Human Cancer Cells with Ever-Shorter Telomeres. Cell Rep. 2017;19:2544-2556 pubmed publisher

Park J, Paik W, Lee K, Ryu J, Lee S, Kim Y. DAXX/ATRX and MEN1 genes are strong prognostic markers in pancreatic neuroendocrine tumors. Oncotarget. 2017;8:49796-49806 pubmed publisher

Fürtjes G, Heß K, Wagner A, Senner V, Brokinkel C, Stummer W, et al. Letter: Retention of ATRX and DAXX Expression in Meningiomas. Neurosurgery. 2017;81:E22-E23 pubmed publisher

Mohamed A, Romano D, Saveanu A, Roche C, Albertelli M, Barbieri F, et al. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?. Oncotarget. 2017;8:41044-41063 pubmed publisher

Vandenbussche C, Allison D, Graham M, Charu V, Lennon A, Wolfgang C, et al. Alternative lengthening of telomeres and ATRX/DAXX loss can be reliably detected in FNAs of pancreatic neuroendocrine tumors. Cancer Cytopathol. 2017;125:544-551 pubmed publisher

Lin C, Wang L, Wang S, Chang Y, Wu Y, Chen H, et al. Daxx inhibits hypoxia-induced lung cancer cell metastasis by suppressing the HIF-1?/HDAC1/Slug axis. Nat Commun. 2016;7:13867 pubmed publisher

Kim J, Brosnan Cashman J, An S, Kim S, Song K, Kim M, et al. Alternative Lengthening of Telomeres in Primary Pancreatic Neuroendocrine Tumors Is Associated with Aggressive Clinical Behavior and Poor Survival. Clin Cancer Res. 2017;23:1598-1606 pubmed publisher

Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, et al. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2016;23:759-67 pubmed publisher

Slatter T, Hsia H, Samaranayaka A, Sykes P, Clow W, Devenish C, et al. Loss of ATRX and DAXX expression identifies poor prognosis for smooth muscle tumours of uncertain malignant potential and early stage uterine leiomyosarcoma. J Pathol Clin Res. 2015;1:95-105 pubmed publisher

Vinagre J, Nabais J, Pinheiro J, Batista R, Oliveira R, Gonçalves A, et al. TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes. Sci Rep. 2016;6:29714 pubmed publisher

Singhi A, Liu T, Roncaioli J, Cao D, Zeh H, Zureikat A, et al. Alternative Lengthening of Telomeres and Loss of DAXX/ATRX Expression Predicts Metastatic Disease and Poor Survival in Patients with Pancreatic Neuroendocrine Tumors. Clin Cancer Res. 2017;23:600-609 pubmed publisher

Yoshida M, Ogawa R, Yoshida H, Maeshima A, Kanai Y, Kinoshita T, et al. TERT promoter mutations are frequent and show association with MED12 mutations in phyllodes tumors of the breast. Br J Cancer. 2015;113:1244-8 pubmed publisher

Napier C, Huschtscha L, Harvey A, Bower K, Noble J, Hendrickson E, et al. ATRX represses alternative lengthening of telomeres. Oncotarget. 2015;6:16543-58 pubmed

Pipinikas C, Dibra H, Karpathakis A, Feber A, Novelli M, Oukrif D, et al. Epigenetic dysregulation and poorer prognosis in DAXX-deficient pancreatic neuroendocrine tumours. Endocr Relat Cancer. 2015;22:L13-8 pubmed publisher

Fishbein L, Khare S, Wubbenhorst B, Desloover D, D Andrea K, Merrill S, et al. Whole-exome sequencing identifies somatic ATRX mutations in pheochromocytomas and paragangliomas. Nat Commun. 2015;6:6140 pubmed publisher

Geis C, Fendrich V, Rexin P, Di Fazio P, Bartsch D, Ocker M, et al. Ileal neuroendocrine tumors show elevated activation of mammalian target of rapamycin complex. J Surg Res. 2015;194:388-93 pubmed publisher